NovaBridge Biosciences (NBP) Exchange Rate Effect (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Exchange Rate Effect of $187000.0 for Q4 2025, up 3216.67% year-over-year from $5638.2 in Q4 2024, and up 156.16% quarter-over-quarter from $73000.0 in Q3 2025.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Exchange Rate Effect (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Exchange Rate Effect for 4 consecutive years, with $187000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Exchange Rate Effect rose 3216.67% year-over-year to $187000.0; the TTM figure through Dec 2025 stood at $853000.0 (up 104.81% YoY), while the FY2025 annual figure was $276000.0, down 51.83% from the prior year.
- Exchange Rate Effect rose to $187000.0 in Q4 2025 per NBP's latest filing, from $73000.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $599000.0 in Q3 2024 and bottomed at -$6000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 275.91 Mn |
| Sep 30, 2025 | 73,000.00 |
| Dec 31, 2024 | -6,000.00 |
| Sep 30, 2024 | 599,000.00 |
| Dec 31, 2020 | -17.61 Mn |
| Sep 30, 2020 | -3.23 Mn |
| Dec 31, 2019 | -8.86 Mn |